Zuellig Pharma
Concise Prescribing Info
NIDDM associated w/ adapted diet in cases where dietary measures alone provide inadequate control of blood glucose levels.
Dosage/Direction for Use
Patient <65 yr Initially 1 tab daily. Maintenance: 1-3 tab daily or 4 tab daily in exceptional cases. Standard dose: 2 tab daily as 2 divided doses. Patient >65 yr Initially ½ tab once daily, may be increased progressively until controlled.
Should be taken with food: Take immediately before meals.
Hypersensitivity to gliclazide, other sulphonylurea or sulphonamides. Type 1 diabetes. Diabetic pre-coma & coma, diabetic ketoacidosis. Concomitant use w/ miconazole. Severe renal or hepatic insufficiency. Lactation.
Special Precautions
Increased risk of hypoglycaemia due to low-calorie diet, prolonged or strenuous exercise, alcohol intake or if used w/ other hypoglycaemics; malnutrition, irregular mealtimes, skipping meals, fasting or dietary changes; imbalance between physical exercise & carbohydrate intake; overdosage; thyroid disorders, hypopituitarism & adrenal insufficiency. G6PD-deficiency. Dysglycaemia; porphyria. Ensure appropriate diet & regular physical exercise. Regularly monitor blood glucose levels & glycated Hb levels. Concomitant treatment w/ St. John's wort (Hypericum perforatum), fluoroquinolones. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Renal & hepatic insufficiency. Avoid use during pregnancy. Childn & adolescents. Elderly.
Adverse Reactions
Hypoglycaemia; GI disturbances eg, abdominal pain, nausea, vomiting, dyspepsia, diarrhoea, constipation.
Drug Interactions
Increased hypoglycaemic effect w/ miconazole systemic/oromucosal gel, systemic phenylbutazone, alcohol. Potentiated blood glucose-lowering effect w/ other antidiabetic agents (insulins, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H2-receptor agonists, MAOIs, sulfonamides, clarithromycin, NSAIDs. Diabetogenic effect of danazol. Increased blood glucose levels w/ chlorpromazine, glucocorticoids, ritodrine, salbutamol, terbutaline IV. Decreased exposure by St. John's wort. Risk of dysglycaemia w/ fluoroquinolones. Potentiated anticoagulation w/ warfarin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Diamicron tab 80 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in